Targeted Alpha-Particle Therapy: A Review of Current Trials

Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted alpha emitters are in current development for several potential oncologic indications. Herein, we review the three most prevalently studied conjugated/chelated alpha emitters (225actinium, 212lead, and 211astatine) and focus on contemporary clinical trials in an effort to more fully appreciate the breadth of the current evaluation. Phase I trials targeting multiple diseases are now underway, and at least one phase III trial (in selected neuroendocrine cancers) is currently in the initial stages of recruitment. Combination trials are now also emerging as alpha emitters are integrated with other therapies in an effort to create solutions for those with advanced cancers. Despite the promise of targeted alpha therapies, many challenges remain. These challenges include the development of reliable supply chains, the need for a better understanding of the relationships between administered dose and absorbed dose in both tissue and tumor and how that predicts outcomes, and the incomplete understanding of potential long-term deleterious effects of the alpha emitters. Progress on multiple fronts is necessary to bring the potential of targeted alpha therapies into the clinic.

[1]  Siddharth Singh,et al.  ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis. , 2023, Journal of Clinical Oncology.

[2]  N. Bander,et al.  Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T. , 2023, Journal of Clinical Oncology.

[3]  P. Conti,et al.  Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer , 2023, EClinicalMedicine.

[4]  S. Bidlingmaier,et al.  Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac α-Radiotherapeutics , 2023, The Journal of Nuclear Medicine.

[5]  F. Solé,et al.  The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw , 2023, Cancers.

[6]  N. Bander,et al.  Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. , 2023, Journal of Clinical Oncology.

[7]  P. Albertsson,et al.  Astatine-211 based radionuclide therapy: Current clinical trial landscape , 2023, Frontiers in Medicine.

[8]  A. Desai,et al.  Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features , 2022, Blood.

[9]  R. Schibli,et al.  [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617 , 2022, Cancers.

[10]  B. Cornelissen,et al.  Imaging PARP with [18F]rucaparib in pancreatic cancer models , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  B. Slusher,et al.  Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects , 2022, Frontiers in Chemistry.

[12]  F. Borgna,et al.  Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy. , 2022, Molecular pharmaceutics.

[13]  M. McDevitt,et al.  [18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response , 2022, bioRxiv.

[14]  M. Morris,et al.  Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. , 2022, Journal of Clinical Oncology.

[15]  E. Delpassand,et al.  Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial , 2022, The Journal of Nuclear Medicine.

[16]  D. Chuvilin,et al.  212Pb: Production Approaches and Targeted Therapy Applications , 2022, Pharmaceutics.

[17]  Xiaotang Yang,et al.  Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review , 2021, Frontiers in Oncology.

[18]  F. Haddad,et al.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight” , 2021, Pharmaceutics.

[19]  S. Vallabhajosula,et al.  Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). , 2021 .

[20]  S. Vallabhajosula,et al.  A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). , 2021 .

[21]  F. Wuest,et al.  Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications , 2020, Pharmaceutics.

[22]  K. Kamaleshwaran,et al.  Whole-body and Single-Photon Emission Computed Tomography/Computed Tomography Postpeptide Receptor Alpha Radionuclide Therapy Images of Actinium 225-Tetraazacyclododecanetetraacetic Acid–Octreotide as a Primary Modality of Treatment in a Patient with Advanced Rectal Neuroendocrine Tumor with Metasta , 2020, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[23]  S. McMahon,et al.  Targeted Alpha Therapy: Current Clinical Applications. , 2020, Cancer biotherapy & radiopharmaceuticals.

[24]  B. Mittal,et al.  225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks. , 2020, Clinical nuclear medicine.

[25]  Yi-Jen Chen,et al.  Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. , 2020, Cancer biotherapy & radiopharmaceuticals.

[26]  F. Borgna,et al.  Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity , 2020, Theranostics.

[27]  E. Azzam,et al.  Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with 223Ra: The Role of Bystander Effects and Their Potential for Therapy , 2019, The Journal of Nuclear Medicine.

[28]  S. R. Bellia,et al.  Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report , 2019, Journal of contemporary brachytherapy.

[29]  F. Saad,et al.  A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. , 2019, Journal of Clinical Oncology.

[30]  I. Navarro-Teulon,et al.  Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy , 2019, Clinical Cancer Research.

[31]  M. Berger,et al.  A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) , 2019, Journal of Medical Imaging and Radiation Sciences.

[32]  James M. Kelly,et al.  Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window , 2018, The Journal of Nuclear Medicine.

[33]  F. Malavasi,et al.  CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma , 2018, Front. Immunol..

[34]  B. Cornelissen,et al.  PET Imaging of PARP Expression Using 18F-Olaparib , 2018, The Journal of Nuclear Medicine.

[35]  Justin J. Wilson,et al.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches. , 2018, Cancer biotherapy & radiopharmaceuticals.

[36]  James M. Kelly,et al.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Yoichi M. Ito,et al.  Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  M. Schwaiger,et al.  Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy , 2017, Chemistry.

[39]  R. Schibli,et al.  Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics , 2016, EJNMMI Radiopharmacy and Chemistry.

[40]  M. Brechbiel,et al.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. , 2015, AIMS medical science.

[41]  H. Wolterbeek,et al.  A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters? , 2015, Pharmaceuticals.

[42]  U. Haberkorn,et al.  PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[43]  F. Bruchertseifer,et al.  Antitumor immunity induced after α irradiation. , 2014, Neoplasia.

[44]  A. S. Sobolev,et al.  Malignant melanoma and melanocortin 1 receptor , 2013, Biochemistry (Moscow).

[45]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[46]  Christie M. Orschell,et al.  Long-Term Hematopoietic Stem Cell Damage in a Murine Model of the Hematopoietic Syndrome of the Acute Radiation Syndrome , 2012, Health physics.

[47]  B. Oborn,et al.  Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. , 2012, Medical physics.

[48]  D. Scheinberg,et al.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. , 2008, Advanced drug delivery reviews.

[49]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[50]  S. Kennel,et al.  Comparison of 225actinium chelates: tissue distribution and radiotoxicity. , 1999, Nuclear medicine and biology.

[51]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[52]  S. Morikawa,et al.  Expression of Leukocyte Common Antigen (CD45) on Various Human Leukemia/Lymphoma Cell Lines , 1990, Acta pathologica japonica.

[53]  A. Partin,et al.  Tumor markers: an update on human kallikrein 2. , 2000, Reviews in urology.

[54]  T. Turkington,et al.  Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. , 1995, Nuclear medicine and biology.